Observations placeholder
Xalkori
Identifier
020378
Type of Spiritual Experience
Number of hallucinations: 7
Background
A description of the experience
Crizotinib (trade name Xalkori), is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
On Jan, 12, 2017 4,439 people reported to have side effects when taking Xalkori.
Among them, 7 people (0.16%) have Hallucination
On Jan, 28, 2016: 749 people reported to have side effects when taking Xalkori. Among them, 135 people (18.02%) have Death.
Time on Xalkori when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 45.45% | 45.45% | 9.09% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Xalkori :
| Female | Male | |
| Death | 51.35% | 48.65% |
Age of people who have Death when taking Xalkori :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13.04% | 23.91% | 63.04% |
Top conditions involved for these people :
- Lung neoplasm malignant (66 people, 48.89%)
- Non-small cell lung cancer (13 people, 9.63%)
- Bronchial carcinoma (8 people, 5.93%)
- Bronchial neoplasm (4 people, 2.96%)
- Lung disorder (3 people, 2.22%)